XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

Employees - 2, CEO - Allen Warren Davidoff, Sector - Healthcare, Country - CA, Market Cap -

Altman ZScore(max is 10): -6.34, Piotroski Score(max is 10): 0, Working Capital: $1917566, Total Assets: $4092091, Retained Earnings: $-21155661, EBIT: -3113130, Total Liabilities: $757539, Revenue: $0

AryaFin Target Price - $1.25 - Current Price $ - Analyst Target Price $